Companies: 10,795·Total market cap: $144.5T

CytoMed Therapeutics Limited

CytoMed Therapeutics Limited

GDTCNASDAQHealthcare● Active

$1.15

$-0.14(-10.85%)

Market Cap$13607760

P/E Ratio—

52W High$3.68

52W Low$0.68

Avg Volume14K

Open$1.14

Beta-0.04

Net Income Financials Revenue

CytoMed Therapeutics Limited (GDTC) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

GDTC · net income · updated Jun 9, 2026

Core profitability metrics

GDTC · net income · margin · TTM · CAGR

Net income was −$3.9M for FY2025 (fiscal year ending 2025-12-31), down 52.3% year-over-year. Net profit margin was -1227.1%.

FY2025 Net Income−$3.9M▼ -52.3% YoY

Trailing 12M (TTM)−$5.5Mtrailing 4 quarters sum

Net Profit Margin< −999%−$3.9M ÷ $319,201

YoY Change-52.3%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 9, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %

▸ FMP /income-statement · Annual · GDTC net income history · GDTC profit margin

Annual net income data

GDTC · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2025Loss−$3.9M▼ 52.3%-1227.1%$319,201

FY2024Loss−$2.6M▲ +38.0%-3699.7%$69,501

FY2023Loss−$4.1M▼ 35.6%-814.0%$509,125

FY2022Loss−$3.1M▼ 47.3%-835.7%$365,604

FY2021Loss−$2.1M▼ 6.8%—$0

Net income vs peers (Healthcare)

GDTC vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

#1

CytoMed Therapeutics LimitedYOU

GDTC

−$3.9M-52.3%-1227.1%

Loss

Johnson & Johnson

$26.80B+90.6%28.5%

Eli Lilly and Company

$20.64B+94.9%31.7%

UnitedHealth Group Incorporated

$12.06B-16.3%2.7%

$4.23B-1.2%6.9%

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

CytoMed Therapeutics Limited (GDTC) reported net income of −$3.9M for FY2025 (fiscal year ending 2025-12-31), down 52.3% year-over-year. The net profit margin was -1227.1% — meaning the company kept $-12.27 of every dollar of revenue as profit.

CytoMed Therapeutics Limited has not yet achieved annual profitability based on available data (7 fiscal years). The company has reported net losses across all available periods.

CytoMed Therapeutics Limited's net profit margin was -1227.1% for FY2025, based on the latest annual results.

Investors sometimes search for "CytoMed Therapeutics Limited net worth" — the company's market capitalization is a separate figure from GDTC net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

GDTC net income · 4 questions

CytoMed Therapeutics Limited is not currently profitable on an annual basis. The company reported a net loss of $3.9M for FY2025.

is GDTC profitabledoes GDTC make a profitGDTC profitabilityGDTC profitable company

▸ Source: FMP /income-statement · GAAP · CytoMed Therapeutics Limited · CytoMed Therapeutics Limited SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026